Merus
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Merus and other ETFs, options, and stocks.About MRUS
Merus NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors.
CEOSven Ante Lundberg
CEOSven Ante Lundberg
Employees260
Employees260
HeadquartersUtrecht, Utrecht
HeadquartersUtrecht, Utrecht
Founded2003
Founded2003
Employees260
Employees260
MRUS Key Statistics
Market cap2.79B
Market cap2.79B
Price-Earnings ratio-9.81
Price-Earnings ratio-9.81
Dividend yield—
Dividend yield—
Average volume873.64K
Average volume873.64K
High today$41.91
High today$41.91
Low today$39.60
Low today$39.60
Open price$40.98
Open price$40.98
Volume643.37K
Volume643.37K
52 Week high$61.61
52 Week high$61.61
52 Week low$33.19
52 Week low$33.19
MRUS News
TipRanks 1d
Merus’s Superior Clinical Execution and Strategic Advancements Drive Buy RatingLifeSci Capital analyst Charles Zhu maintained a Buy rating on Merus (MRUS – Research Report) yesterday and set a price target of $110.00. Protect Your Portfol...
TipRanks 2d
Merus’s Promising ASCO Presentation: A Catalyst for Growth with Buy Rating from Matt PhippsWilliam Blair analyst Matt Phipps has reiterated their bullish stance on MRUS stock, giving a Buy rating on May 8. Protect Your Portfolio Against Market Uncert...
Analyst ratings
100%
of 18 ratingsBuy
100%
Hold
0%
Sell
0%
People also own
Based on the portfolios of people who own MRUS. This list is generated using Robinhood data, and it’s not a recommendation.